COVID-19：イベルメクチンとドキシサイクリン： Bangladesh医大（動画）：
Bangladesh Med College Prospective Study: Ivermectin & Doxycycline：
孟加拉国研究的同行评审结果：伊维菌素和强力霉素联合使用
COVID-19：
2020年9月23日
バングラデシュ医科大学：
バングラデシュ医科大学タレク・アラム博士が、COVID-19シリーズ研究を上梓しました。
ドキシサイクリン、イベルメクチン：
TrialSiteが、アラム博士とのインタビュー内容を、お伝えします。
「イベルメクチンとドキシサイクリンの組み合わせ治療：100人のCOVID-19陽性患者の症例シリーズ」との研究発表です。
バングラデシュ医学雑誌：調査結果
調査結果：
SARS-CoV-2に感染した、軽度・中等度患者を治療で、イベルメクチンとドキシサイクリンを組み合わせ投与。
COVID-19感染した100人の患者：
8歳から84歳までの男性64人と女性36人の患者が対象。
- 適応外併用療法の投与後、すべての患者が陰性になりました。
- また症状も、72時間以内に著しく改善しました。
- 顕著な副作用も出ていません。
The study team
concluded in this peer-reviewed report that ivermectin and doxycycline were “found to be very effective in viral clearance in mild and moderately sick COVID-19 patients.”
Randomized Trial Moves Forward As mentioned previously, Dr. Alam informed TrialSite that the authorities in Bangladesh have approved the randomized controlled trial based on the efforts of his work to date.
TrialSite reported that Dr. Alam was first planning this study to further investigate “the People’s Medicine” back in July.
the world 8th most populated nation, are not trivial nor remote.
Rather, they reflect a growing real-world evidence that national research agencies, including the National Institutes of Health in the United States,
should undertake larger multicenter studies to validate and recommend this combination therapy to include in national COVID-19 guidelines.
Called “The People’s Medicine” in Bangladesh, the time is now for formalized study in the United States.
As COVID-19 continues to wreak havoc around the world—as of this writing, 31 million reported cases worldwide with nearly 1 million deaths (200,000 in America alone)—health, economies, and civil societies feel the growing strain.
Cost effective and widely available treatments must be found to economically and expeditiously address and contain this contagion.
A study of ivermectin isn’t a replacement for the mission-critical vaccines (Moderna, Pfizer, etc.) and powerful monoclonal antibodies under development by Regeneron, Eli Lilly and others.
Rather, they all complement another as a range of therapies at different price points are required to take on COVID-19 for the long run